An approach to pruritus in atopic dermatitis: A critical systematic review of the tacrolimus ointment literature

Journal of Drugs in Dermatology

Volumn 9, Issue 5, 2010, Pages 488-498

  Fleischer Jr , Alan B ^a   Boguniewicz, Mark ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCLOMETASONE DIPROPIONATE; BETAMETHASONE VALERATE; CORTICOSTEROID; FILAGGRIN; HISTAMINE; HYDROCORTISONE ACETATE; HYDROCORTISONE BUTYRATE; METHYLPREDNISOLONE ACEPONATE; NEUROPEPTIDE; PIMECROLIMUS; PROTEINASE; TACROLIMUS; TRYPTASE; CALCINEURIN; IMMUNOSUPPRESSIVE AGENT;

APPLICATION SITE BURNING; APPLICATION SITE ERYTHEMA; APPLICATION SITE IRRITATION; APPLICATION SITE PRURITUS; ATOPIC DERMATITIS; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EARLY INTERVENTION; ELECTRIC CURRENT; GENE MUTATION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; KERATINOCYTE; LYMPHOMA; MEDIATOR; MEDLINE; NERVE FIBER; NEUROPHYSIOLOGY; PATHOPHYSIOLOGY; PERCEPTIVE THRESHOLD; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; REVIEW; SKIN CANCER; SKIN PRURITUS; SKIN STRUCTURE; SLEEP QUALITY; SYSTEMATIC REVIEW; TRANSCUTANEOUS NERVE STIMULATION; VISUAL ANALOG SCALE; ADOLESCENT; ADULT; CHILD; CLINICAL TRIAL; DRUG ANTAGONISM; HOSPITALIZATION; INTRADERMAL DRUG ADMINISTRATION; OINTMENT; PRESCHOOL CHILD; PRURITUS;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; CALCINEURIN; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DERMATITIS, ATOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; OINTMENTS; PRURITUS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TACROLIMUS;

EID: 77953172905     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Abramovits W. Atopic dermatitis. J Am Acad Dermatol. 2005;53:S86-S93. (Pubitemid 40828185)
2. Kim DW, Park JY, Na GY, et al. Correlation of clinical features and skin barrier function in adolescent and adult patients with atopic dermatitis. Int J Dermatol. 2006;45:698-701.
3. Cork MJ, Robinson DA, Vasilopoulos Y, et al. New perspectives on epidermal barrier dysfunction in atopic dermatitis: Gene-environment interactions. J Allergy Clin Immunol. 2006;118:3-21. (Pubitemid 43946484)
4. Elias PM, Steinhoff M. "Outside-to-inside" (and now back to "Outside") pathogenic mechanisms in atopic dermatitis. J Invest Dermatol. 2008;128:1067-1070. (Pubitemid 351543225)
5. Ständer S, Steinhoff M. Pathophysiology of pruritus in atopic dermatitis: An overview. Exp Dermatol. 2002;11:12-24. (Pubitemid 36934620)
6. Yosipovitch G, Fleischer A. Itch associated with skin disease: Advances in pathophysiology and emerging therapies. Am J Clin Dermatol. 2003;4:617-622. (Pubitemid 37114950)
7. Yosipovitch G, Papoiu AD. What causes itch in atopic dermatitis? Curr Allergy Asthma Rep. 2008;8:306-311.
8. Sonkoly E, Muller A, Lauerma AI, et al. Il-31: A new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol. 2006;117:411-417. (Pubitemid 43192023)
9. Pincelli C, Fantini F, Massimi P, et al. Neuropeptides in skin from patients with atopic dermatitis: An immunohistochemical study. Br J Dermatol. 1990;122:745-750. (Pubitemid 20182190)
10. Rukwied R, Lischetzki G, Mcglone F, et al. Mast cell mediators other than histamine induce pruritus in atopic dermatitis patients: A dermal microdialysis study. Br J Dermatol. 2000;142:1114-1120. (Pubitemid 30418296)
11. Herman SM, Vender RB. Antihistamines in the treatment of dermatitis. J Cutan Med Surg. 2003;7:467-473.
12. Steinhoff M, Neisius U, Ikoma A, et al. Proteinase-activated receptor-2 mediates itch: A novel pathway for pruritus in human skin. J Neurosci. 2003;23:6176-6180. (Pubitemid 36875617)
13. Demerjian M, Hachem JP, Tschachler E, et al. Acute modulations in permeability barrier function regulate epidermal cornification: Role of caspase-14 and the protease-activated receptor type 2. Am J Pathol. 2008;172:86-97. (Pubitemid 351186371)
14. McGrath JA. Filaggrin and the great epidermal barrier grief. Australas J Dermatol. 2008;49:67-73.
15. McGrath JA, Uitto J. The filaggrin story: Novel insights into skin-barrier function and disease. Trends Mol Med. 2008;14:20-27.
16. Giannetti A, Fantini F, Cimitan A, Pincelli C. Vasoactive intestinal polypeptide and substance P in the pathogenesis of atopic dermatitis. Acta Derm Venereol Suppl (Stockh). 1992;176:90-92.
17. Tobin D, Nabarro G, Baart de la Faille H, et al. Increased number of immunoreactive nerve fibers in atopic dermatitis. J Allergy Clin Immunol. 1992;90:613-622.
18. Kang S, Lucky AW, Pariser D, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol. 2001;44:S58-S64. (Pubitemid 32047913)
19. Yosipovitch G. Assessment of itch: More to be learned and improvements to be made. J Invest Dermatol. 2003;121:xiv-xv.
20. Kobayashi H, Kikuchi K, Tsubono Y, Tagami H. Measurement of electrical current perception threshold of sensory nerves for pruritus in atopic dermatitis patients and normal individuals with various degrees of mild damage to the stratum corneum. Dermatology. 2003;206:204-211. (Pubitemid 36407826)
21. Hon KL, Lam MC, Leung TF, et al. Assessing itch in children with atopic dermatitis treated with tacrolimus: Objective versus subjective assessment. Adv Ther. 2007;24:23-28.
22. Ruzicka T, Bieber T, Schopf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med. 1997;337:816-821. (Pubitemid 27391631)
23. Boguniewicz M, Fiedler VC, Raimer S, et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol. 1998;102:637-644.
24. Hanifin JM, Ling MR, Langley R, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part I, efficacy. J Am Acad Dermatol. 2001;44:S28-S38. (Pubitemid 32047911)
25. Paller A, Eichenfield LF, Leung DY, et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol. 2001;44:S47-S57. (Pubitemid 32049029)
26. Schachner LA, Lamerson C, Sheehan MP, et al. Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: Results from a randomized, double-blind, vehicle-controlled study. Pediatrics. 2005;116:e334-e342. (Pubitemid 44336646)
27. Chapman MS, Schachner LA, Breneman D, et al. Tacrolimus ointment 0.03% shows efficacy and safety in pediatric and adult patients with mild to moderate atopic dermatitis. J Am Acad Dermatol. 2005;53:S177-S185. (Pubitemid 40966764)
28. Paller AS, Lebwohl M, Fleischer AB, Jr., et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: Results from 3 randomized, comparative studies. J Am Acad Dermatol. 2005;52:810-822. (Pubitemid 40614645)
29. Kempers S, Boguniewicz M, Carter E, et al. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol. 2004;51:515-525. (Pubitemid 39278069)
30. Reitamo S, Van Leent EJ, Ho V, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol. 2002;109:539-546. (Pubitemid 34234208)
31. Reitamo S, Harper J, Bos JD, et al. 0.03% tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: Results of a randomized double-blind controlled trial. Br J Dermatol. 2004;150:554-562. (Pubitemid 38446313)
32. Reitamo S, Rustin M, Ruzicka T, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol. 2002;109:547-555. (Pubitemid 34234209)
33. Reitamo S, Ortonne JP, Sand C, et al. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol. 2005;152:1282-1289. (Pubitemid 40933430)
34. Hanifin J, Boguniewicz M, Kang S, Reitamo S. Tacrolimus for the early relief from itching in adults and children with atopic dermatitis. J Am Acad Dermatol. 2008;58:Abstract P604.
35. FK-506 Ointment Study Group. Phase III comparative study of FK506 ointment. Group comparison study with alclometasone dipropionate in atopic dermatitis: Face and neck. Acta Dermatol (Kyoto). 1997;92:277-288.
36. Nakagawa H. Comparison of the efficacy and safety of 0.1% tacrolimus ointment with topical corticosteroids in adult patients with atopic dermatitis: Review of randomised, double-blind clinical studies conducted in Japan. Clin Drug Investig. 2006;26:235-246. (Pubitemid 43845689)
37. Bieber T, Vick K, Folster-Holst R, et al. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy. 2007;62:184-189. (Pubitemid 46090301)
38. Remitz A, Harper J, Rustin M, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. Acta Derm Venereol. 2007;87:54-61. (Pubitemid 46225392)
39. Reitamo S, Wollenberg A, Schopf E, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol. 2000;136:999-1006. (Pubitemid 30629127)
40. Simpson D, Noble S. Tacrolimus ointment: A review of its use in atopic dermatitis and its clinical potential in other inflammatory skin conditions. Drugs. 2005;65:827-858. (Pubitemid 40598095)
41. Rustin MH. The safety of tacrolimus ointment for the treatment of atopic dermatitis: A review. Br J Dermatol. 2007;157:861-873. (Pubitemid 47583524)
42. Tan J, Langley R. Safety and efficacy of tacrolimus ointment 0.1% (protopic) in atopic dermatitis: A Canadian open-label multicenter study. J Cutan Med Surg. 2004;8:213-219. (Pubitemid 41223719)
43. Koo JY, Fleischer Jr. AB, Abramovits W, et al. Tacrolimus ointment is safe and effective in the treatment of atopic dermatitis: Results in 8000 patients. J Am Acad Dermatol. 2005;53:S195-205. (Pubitemid 40966766)
44. Soter NA, Fleischer Jr. AB, Webster GF, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part II, safety. J Am Acad Dermatol. 2001;44:S39-S46. (Pubitemid 32047912)
45. FK-506 Ointment Study Group. Phase III comparative study of FK506 ointment versus betamethasone valerate ointment in atopic dermatitis (trunk/extremities). Nishinihon J Dermatol (Japanese). 1997;59:870-879.
46. Astellas Pharma US I. Protopic prescribing information. Available at http://www.protopic.com/UserFiles/File/pdf/full-prescribing.pdf. Accessed August 11, 2008.
47. Novartis Pharmaceuticals Corp. Elidel prescribing information. Available at http://www.pharma.us.novartis.com/product/pi/pdf/elidel.pdf. Accessed August 11, 2008.
48. Arellano FM, Wentworth CE, Arana A, et al. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol. 2007;127:808-816. (Pubitemid 46434650)
49. Margolis DJ, Hoffstad O, Bilker W. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology. 2007;214:289-295. (Pubitemid 46659010)
50. Arellano FM, Arana A, Wentworth CE, et al. Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom. J Allergy Clin Immunol. 2009;123:1111-1116.
51. Remitz A, Reitamo S. Long-term safety of tacrolimus ointment in atopic dermatitis. Expert Opin Drug Saf. 2009;8:501-506.
52. Ceilley R, Eisenthal A. The unintended effects of a boxed warning. J Clin Aesthetic Dermatol. 2009;2:33-39.
53. Bender BG, Ballard R, Canono B, et al. Disease severity, scratching, and sleep quality in patients with atopic dermatitis. J Am Acad Dermatol. 2008;58:415-420. (Pubitemid 351226301)
54. Bender BG, Leung SB, Leung DY. Actigraphy assessment of sleep disturbance in patients with atopic dermatitis: An objective life quality measure. J Allergy Clin Immunol. 2003;111:598-602. (Pubitemid 36337883)
55. Chamlin SL, Mattson CL, Frieden IJ, et al. The price of pruritus: Sleep disturbance and cosleeping in atopic dermatitis. Arch Pediatr Adolesc Med. 2005;159:745-750. (Pubitemid 41126837)
56. Stores G, Burrows A, Crawford C. Physiological sleep disturbance in children with atopic dermatitis: A case control study. Pediatr Dermatol. 1998;15:264-268. (Pubitemid 28374463)
57. Reuveni H, Chapnick G, Tal A, Tarasiuk A. Sleep fragmentation in children with atopic dermatitis. Arch Pediatr Adolesc Med. 1999;153:249-253. (Pubitemid 29128331)
58. Dahl RE, Bernhisel-Broadbent J, Scanlon-Holdford S, et al. Sleep disturbances in children with atopic dermatitis. Arch Pediatr Adolesc Med. 1995;149:856-860.
59. Holm EA, Wulf HC, Stegmann H, Jemec GB. Life quality assessment among patients with atopic eczema. Br J Dermatol. 2006;154:719-725. (Pubitemid 43374098)
60. Lewis-Jones S. Quality of life and childhood atopic dermatitis: The misery of living with childhood eczema. Int J Clin Pract. 2006;60:984-992. (Pubitemid 44082290)
61. Boguniewicz M, Abramovits W, Paller A, et al. A multiple-domain framework of clinical, economic, and patient-reported outcomes for evaluating benefits of intervention in atopic dermatitis. J Drugs Dermatol. 2007;6:416-423.
62. Otsuki M, Kawashima M, Shibata Y, et al. Efficacy and safety of FK506 (tacrolimus) ointment in children with atopic dermatitis: Phase III double-blinded comparison with vehicle ointment. J Clin Ther Med (Japanese). 2003;19:596-595.
63. Katoh N, Hirano S, Yasuno H, Kishimoto S. Effects of tacrolimus ointment on facial eruption, itch, and scratching in patients with atopic dermatitis. J Dermatol. 2004;31:194-199. (Pubitemid 38478348)
64. Elias PM. Skin barrier function. Curr Allergy Asthma Rep. 2008;8:299-305.
65. Rancé F, Boguniewicz M, Lau S. New visions for atopic eczema: An iPAC summary and future trends. Pediatr Allergy Immunol. 2008;19 Suppl 19:17-25.
66. Park CW, Lee BH, Lee CH. Tacrolimus reduces staphylococcal colonization on the skin in Korean atopic dermatitis patients. Drugs Exp Clin Res. 2005;31:77-87. (Pubitemid 350056459)
67. Xhauflaire-Uhoda E, Thirion L, Piérard-Franchimont C, Piérard GE. Comparative effect of tacrolimus and betamethasone valerate on the passive sustainable hydration of the stratum corneum in atopic dermatitis. Dermatology. 2007;214:328-332. (Pubitemid 46659016)
68. Zuberbier T, Orlow SJ, Paller AS, et al. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol. 2006;118:226-232. (Pubitemid 43946465)